Navigation Links
Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras

LA JOLLA, Calif., Nov. 20, 2013 /PRNewswire/ -- Wellspring Biosciences, a leading biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of cancer, announced today a publication from Kevan Shokat, Ph.D., one of its founders and chairman of its scientific advisory board, in the journal Nature that describes the discovery of small molecules that bind irreversibly to a common oncogenic mutant, K-Ras G12C.

Ras genes are mutated in up to 30% of human cancers and are among the most important therapeutic targets in the treatment of human cancer.  Yet, to date, not a single drug that targets Ras proteins or acts on Ras-driven cancers has been developed successfully.  Indeed, tumors harboring Ras mutations are among the most difficult to treat and are excluded from treatment with many therapies.

Dr. Shokat serves as Professor and Chair in the Department of Cellular and Molecular Pharmacology at UCSF as well as Investigator, Howard Hughes Medical Institute.  "We are extremely excited to find a druggable binding pocket on K-Ras, the most frequently mutated oncogene in human cancer" said Professor Shokat.  "Our findings can serve as the starting point for drug-discovery efforts targeting the G12C form of K-Ras and eventually other cancer causing alleles of K-Ras."

"The proto-oncogene K-Ras is mutated in a wide array of human cancers, most of which are aggressive and respond poorly to standard therapies," said Yi Liu, Ph.D., Chief Scientific Officer of Wellspring Biosciences.  "This represents one of the most promising approaches to target K-Ras yet reported, and we look forward to continuing to advance this exciting science in the potentially transformative area of drug development."

In February 2013, Wellspring Biosciences, through its affiliate Araxes Pharma, entered into an exclusive arrangement with Janssen Biotech, Inc. to develop first-in-class therapeutics against G12C K-Ras for the treatment of cancer.  Under the agreement, Araxes Pharma will advance the program through Phase I to clinical proof-of-concept.  Thereafter, Janssen has an option for the continued development and worldwide commercialization of products arising under the agreement.

The paper, titled "Inhibitors of K-Ras G12C allosterically control GTP affinity and effector interactions" was made available on November 20, 2013 in the advanced online publication of Nature at

About Wellspring Biosciences

Wellspring Biosciences LLC is a privately held, drug discovery and development company committed to creating breakthrough medicines for the treatment of cancer and other serious diseases.  Our team has a proven track record, having previously played pivotal roles in the discovery of clinical-stage compounds for the treatment of cancer and immune-mediated inflammatory diseases at Intellikine.  Araxes Pharma LLC, an affiliate of Wellspring Biosciences, is engaged in an exclusive arrangement with Janssen Biotech, Inc.  Wellspring Biosciences is located in La Jolla, California.  For more information, please visit the company's website at

Contact: Anna Nadolski, 858-500-8803,

SOURCE Wellspring Biosciences LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Springer will publish lecture series with the Mathematical Biosciences Institute
2. Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation
3. Inflection Biosciences licenses preclinical oncology programs from the CNIO
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
6. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
7. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
8. Alfred Russel Wallace: Co-founder of the theory of biological evolution
9. Google, Intel founders support undersea research by UMass Amherst microbiologist
10. Dr. Anurag Agrawal to give Founders Memorial lecture at Entomology 2013
11. Biophysical Society names 2013 Distinguished Service, Emily M. Gray, and Founders awardees
Post Your Comments:
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... Spherix Incorporated (Nasdaq: SPEX ) an ... and monetization of intellectual property, today provided an ... to create shareholder value. Anthony ... on published reports, the total addressable market of ... Spherix will seek to secure fair and reasonable ...
(Date:11/30/2015)...  HUYA Bioscience International, the leader in accelerating global ... today announced it has signed a Memorandum of Understanding ... collaboration between KDDF and HUYA with the ultimate goal ... for the global market. China,s ... innovative preclinical and clinical stage compounds. The company advances ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... MarkLogic, the Enterprise NoSQL database platform provider, creating a seamless approach to ... Content Intelligence capabilities provide a robust set of semantic tools which create ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
Breaking Biology Technology: